January 24, 2019

Oncopeptides has completed a directed share issue of approximately SEK 546 million

January 24, 2019 - Regulatory press release NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRA...
Read more
January 17, 2019

Targovax granted European Patent for mutant-RAS neoantigen platform lead products

Extends IP protection of TG01 and TG02 until 06.05.2034 Oslo, 17 January 2019: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focuse...
Read more
January 11, 2019

Actavis infringes Orexo’s long term Zubsolv® US patent ´330

Uppsala, Sweden – January 11, 2019 – Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the Unit...
Read more
January 7, 2019

Modus Therapeutics completes enrollment of randomized, placebo-controlled Phase II clinical trial evaluating sevuparin for management of Acute Vaso-Occlusive Crisis in SCD patients

STOCKHOLM, SWEDEN – 07 January 2019: Modus Therapeutics AB, a company developing innovative treatments in high unmet medical need disease areas with a focus on sickle cell diseas...
Read more
January 7, 2019

Aprea Therapeutics Announces Presentation at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco

BOSTON and STOCKHOLM, Jan. 7, 2019 /PRNewswire/ -- Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting t...
Read more
January 7, 2019

Positive results from human PK study assessing Orexo’s new intranasal naloxone formulations for opioid overdose reversal

Uppsala, Sweden – January 7, 2019. Orexo AB (publ), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces positive results f...
Read more
January 4, 2019

BONESUPPORT appoints Annelie Aava Vikner as Executive Vice President Global Marketing & Communications

Lund, Sweden, 8:00 CET, January 4 2019 – BONESUPPORT™ an emerging leader in Orthobiologics for the management of bone voids, announces changes in its leadership team that...
Read more
January 4, 2019

Rainier Therapeutics Expands Leadership Team to Prepare for Late-Stage Clinical Trials

SAN LEANDRO, Calif., January 3, 2019 — Rainier Therapeutics, Inc., a privately-held clinical stage drug development company focused on helping patients in the high unmet need...
Read more
January 2, 2019

Nordic Nanovector appoints Mark Wright as Head of Manufacturing

Oslo, Norway, 2 January 2019 Nordic Nanovector ASA (OSE: NANO) announces the appointment of Dr Mark Wright as Head of Manufacturing. He joins the company today a...
Read more
December 19, 2018

Strongbridge Biopharma plc Announces Closing of Transaction with Novo Nordisk to Transfer the Rights to MACRILEN™ (macimorelin) in the United States and Canada

Strongbridge Used Portion of $145 Million Upfront Cash Payment from Novo Nordisk to Fully Repay Outstanding Debt DUBLIN, Ireland and TREVOSE, Pa., Dec. 19, 2018 (GLOBE NEWSWIR...
Read more